Pregnancy Screening Tests by Trimester | Complete Clinical Guide

Pregnancy Screening Tests by Trimester | Complete Clinical Guide

Understanding pregnancy screening tests by trimester is an essential aspect of modern maternal and fetal medicine. Pregnancy is a dynamic biological process that requires systematic monitoring to verify fetal growth, evaluate genetic risk, identify structural variations, and safeguard maternal metabolic health.

Antenatal care relies on a structured sequence of non-invasive screening tests administered across the first, second, and third trimesters. Unlike diagnostic procedures—which provide definitive answers by directly sampling fetal cells—screening tests evaluate statistical probabilities and biological markers. This approach allows expectant parents and obstetric clinicians to identify potential concerns early and make informed decisions about delivery planning and clinical management.

Core Principles: Screening vs. Diagnostic Testing

To navigate antenatal care effectively, it is necessary to distinguish between screening tests and diagnostic tests.

                   PRENATAL EVALUATION CATEGORIES
                                 │
     ┌───────────────────────────┴───────────────────────────┐
     ▼                                                       ▼
[SCREENING TESTS]                                   [DIAGNOSTIC TESTS]
 • Calculates risk probability                       • Provides definitive diagnosis
 • Non-invasive (Blood draws, Ultrasounds)           • Invasive (CVS, Amniocentesis)
 • Zero risk to mother or fetus                      • Minor procedure-related risk (~0.1-0.5%)
 • Applied universally across trimesters             • Offered when screening indicates elevated risk

1. Screening Tests: Calculate the risk or probability that a baby may have a specific health condition or structural variation. Because they use non-invasive methods such as maternal blood draws and ultrasound imaging, screening tests carry no risk of pregnancy loss and are recommended for all pregnant individuals.
2. Diagnostic Tests: Determine with near-total accuracy whether a specific genetic or chromosomal condition is present. Procedures such as Chorionic Villus Sampling (CVS) or Amniocentesis collect fetal tissue (placental cells or amniotic fluid cells) for karyotyping, microarrays, or gene sequencing. Because these procedures carry a slight risk of complication (less than 0.5%), they are typically reserved for cases where a screening test indicates an elevated risk.

Complete Antenatal Screening Master Timeline

                             PREGNANCY SCREENING MASTER TIMELINE
                                              │
 ┌────────────────────────────────────────────┼────────────────────────────────────────────┐
 ▼                                            ▼                                            ▼
[FIRST TRIMESTER: Weeks 1–13+6]             [SECOND TRIMESTER: Weeks 14–27+6]           [THIRD TRIMESTER: Weeks 28–40]
 • Baseline Blood & Urine Panel              • Quadruple Marker (Wks 15–20)               • Oral Glucose Tolerance (Wks 24–28)
 • NIPT / Cell-Free DNA (Wk 10+)             • TIFFA Anomaly Scan (Wks 18–22)             • Growth & Color Doppler (Wks 28–34)
 • NT Scan + Double Marker (Wks 11–13+6)     • Fetal Echocardiogram (Wks 20–24)          • GBS Bacterial Culture (Wks 36–37)

First Trimester Screening Tests (Weeks 1 to 13+6)

The first trimester focuses on establishing baseline maternal health, confirming intrauterine viability, calculating precise gestational age, and assessing early chromosomal risk.

┌────────────────────────────────────────────────────────────────────────┐
│                   FIRST TRIMESTER SCREENING SUITE                      │
├────────────────────────────────────────────────────────────────────────┤
│  1. Baseline Laboratory Panel (Blood group, Rh, CBC, Infection Screen) │
│  2. Non-Invasive Prenatal Testing / NIPT (Cell-free DNA from Wk 10)    │
│  3. First Trimester Combined Screen (NT Ultrasound + Double Marker)    │
└────────────────────────────────────────────────────────────────────────┘

1. Baseline Maternal Laboratory Panel (Weeks 4 to 10)

During your initial prenatal visit, blood and urine samples establish maternal health baselines and identify treatable conditions:

• Blood Grouping & Rh Typing: Identifies maternal blood type and Rh status (Positive or Negative). If an Rh-negative mother carries an Rh-positive fetus, maternal exposure to fetal blood can trigger antibody production (Rh isoimmunization). Identifying Rh-negativity early ensures timely administration of Anti-D immunoglobulin injections at week 28 and post-delivery.
• Complete Blood Count (CBC): Evaluates hemoglobin ($Hb$) and hematocrit ($Hct$) to screen for maternal anemia. Physiological hemodilution occurs during pregnancy, but hemoglobin dropping below $11.0 \text{ g/dL}$ in the first trimester requires iron supplementation to support oxygen delivery.
• Infectious Disease Screening:
  • Rubella & Varicella Immunity: Verifies protective IgG antibodies. Non-immune mothers cannot receive live vaccines during pregnancy and must avoid exposure until postpartum vaccination.
  • Viral Panel (HIV, Hepatitis B, Hepatitis C): Routine screening prevents mother-to-child transmission through early viral suppression regimens and neonatal immunoglobulins.
  • Syphilis Testing (VDRL / RPR): Screening prevents congenital syphilis through early penicillin treatment.
• Baseline Urinalysis & Culture: Detects asymptomatic bacteriuria. Left untreated, asymptomatic urinary bacterial colonization can progress to acute pyelonephritis or trigger preterm labor.

2. First Trimester Combined Screening (Weeks 11 to 13+6)

This standard screening combines ultrasound biometry with biochemical maternal serum markers to evaluate the risk of Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13).

A. Nuchal Translucency (NT) Ultrasound Scan

Conducted between 11 weeks and 13 weeks + 6 days (when fetal Crown-Rump Length [CRL] measures between $45 \text{ mm}$ and $84 \text{ mm}$):

• Fluid Measurement: Measures the subcutaneous fluid-filled space at the back of the fetal neck.
• Clinical Thresholds: An NT measurement under $2.5 \text{ mm}$ is typically considered normal. Measurements $\ge 3.0 \text{ mm}$ (or above the 95th percentile for a given CRL) indicate an increased risk for chromosomal trisomies, genetic syndromes (such as Noonan syndrome), or structural congenital heart defects.
• Nasal Bone (NB) Assessment: The presence or absence of the fetal nasal bone is evaluated alongside NT. An absent or hypoplastic nasal bone in the first trimester is a soft marker for Trisomy 21.

B. First Trimester Double Marker Serum Test

A maternal blood draw measures two placental proteins:

1. Free Beta-Human Chorionic Gonadotropin (Free $\beta$-hCG): Abnormally elevated in Trisomy 21 pregnancies.
2. Pregnancy-Associated Plasma Protein-A (PAPP-A): Abnormally reduced in Trisomy 21 and Trisomy 18 pregnancies.

Risk Calculation: Algorithms process maternal age, weight, ethnicity, NT measurement, nasal bone presence, and Multiples of the Median ($MoM$) for Free $\beta$-hCG and PAPP-A to generate a composite risk ratio (e.g., $1:2,500$ vs. $1:85$).

3. Non-Invasive Prenatal Testing (NIPT / Cell-Free DNA)

Available from 10 weeks of gestation onward, NIPT analyzes circulating cell-free fetal DNA (cfDNA) derived from placental trophoblasts present in maternal blood.

• High Sensitivity: Offers over 99% detection sensitivity for Trisomy 21, with a false-positive rate under 0.1%. It also evaluates Trisomy 18, Trisomy 13, sex chromosome aneuploidies (e.g., Turner syndrome $45,X$; Klinefelter syndrome $47,XXY$), and optional microdeletion syndromes (e.g., 22q11.2 deletion / DiGeorge syndrome).
• Fetal Fraction Requirement: Valid testing requires a minimum “fetal fraction” (the proportion of cfDNA originating from the placenta compared to maternal DNA), usually between 2% and 4%.
• Indication Scope: Recommended for high-risk pregnancies (maternal age $\ge 35$, elevated NT scan, or previous trisomic pregnancy) and widely utilized as a primary screening option for patients seeking comprehensive chromosomal risk estimates.

Second Trimester Screening Tests (Weeks 14 to 27+6)

The second trimester focuses on physical organ anatomy, structural integrity, neural tube development, and cervical stability.

┌────────────────────────────────────────────────────────────────────────┐
│                   SECOND TRIMESTER SCREENING SUITE                     │
├────────────────────────────────────────────────────────────────────────┤
│  1. Quadruple Marker Serum Test (Weeks 15 to 20)                       │
│  2. Targeted Imaging for Fetal Anomalies / TIFFA Scan (Weeks 18 to 22) │
│  3. Fetal Echocardiography & Transvaginal Cervical Length Measurement   │
└────────────────────────────────────────────────────────────────────────┘

1. Second Trimester Quadruple Marker Test (Weeks 15 to 20)

For patients who missed first-trimester screening or require additional neural tube screening, the Quadruple Marker serum panel measures four maternal analytes:

$$\text{Quadruple Marker Serum Analytes}$$

$$\begin{aligned} \text{1. Alpha-Fetoprotein (AFP)} &\longrightarrow \text{Produced by fetal liver; elevated in neural tube defects.} \\ \text{2. Total hCG} &\longrightarrow \text{Produced by placenta; elevated in Trisomy 21.} \\ \text{3. Unconjugated Estriol (uE3)} &\longrightarrow \text{Produced by fetal adrenal glands \& placenta; reduced in trisomies.} \\ \text{4. Inhibin A} &\longrightarrow \text{Produced by placenta; elevated in Trisomy 21.} \end{aligned}$$

Screening Clinical Correlation

• Open Neural Tube Defects (ONTDs): High maternal serum AFP levels (typically $> 2.5 \text{ MoM}$) indicate an increased risk for conditions like spina bifida or anencephaly, where neural tissue remains exposed.
• Down Syndrome Marker Profile: Characterized by reduced AFP, reduced uE3, elevated total hCG, and elevated Inhibin A.

2. Targeted Imaging for Fetal Anomalies (TIFFA / Anomaly Scan)

Performed between weeks 18 and 22, the TIFFA scan is an in-depth ultrasound examination evaluating fetal anatomy, organ placement, and physical development.

                            TIFFA ANOMALY SCAN ANATOMICAL CHECKLIST
                                               │
     ┌──────────────────────┬──────────────────┼──────────────────┬──────────────────────┐
     ▼                      ▼                  ▼                  ▼                      ▼
[CRANIAL & BRAIN]      [FACIAL PROFILE]     [CARDIAC 4-CHAMBER]  [ABDOMEN & RENAL]    [SPINE & LIMBS]
 Lateral Ventricles    Upper Lip & Palate   Ventricular Outflow  Stomach Bubble       33-Segment Vertebrae
 Cerebellum & CM       Eye Orbits & Nasal   Great Vessels Axis   Kidneys & Bladder    All 4 Long Bones & Digits

• Neurosonographic Evaluation: Examines lateral ventricle width (ruling out ventriculomegaly), the cerebellum, and cisterna magna depth (ruling out Arnold-Chiari malformations or spina bifida markers like the “lemon” and “banana” signs).
• Facial Profile: Verifies intact upper lip and secondary palate, screening for cleft lip and palate.
• Cardiovascular Axis: Examines four chambers, cardiac axis, symmetrical ventricular filling, and outflow tract orientation (aorta and pulmonary artery).
• Gastrointestinal & Genitourinary Systems: Verifies a fluid-filled stomach bubble, intact abdominal wall insertion, both renal pelvises, and a functional urinary bladder.
• Musculoskeletal System: Evaluates alignment across the cervical, thoracic, lumbar, and sacral spine, along with three segments in each limb (e.g., femur, tibia/fibula, foot).
• Placental Mapping: Determines placental location relative to the internal cervical os to identify low-lying placenta or placenta previa.

3. Cervical Length Measurement & Fetal Echocardiography

• Transvaginal Cervical Length (TVS Cervix): Evaluates cervical integrity between weeks 18 and 24. A shortened cervical length ($\le 25 \text{ mm}$) indicates an increased risk for spontaneous preterm birth and may warrant preventive care, such as vaginal progesterone or cervical cerclage.
• Fetal Echocardiogram (Weeks 20 to 24): A specialized ultrasound focused on cardiac structures, indicated for mothers with pre-gestational diabetes, autoimmune conditions (e.g., anti-Ro/SSA antibodies), IVF conception, elevated first-trimester NT, or a family history of congenital heart disease.

Third Trimester Screening Tests (Weeks 28 to Delivery)

Third-trimester screening monitors metabolic parameters, fetal growth velocity, placental perfusion, and bacterial colonization prior to labor.

┌────────────────────────────────────────────────────────────────────────┐
│                   THIRD TRIMESTER SCREENING SUITE                      │
├────────────────────────────────────────────────────────────────────────┤
│  1. Oral Glucose Tolerance Test / GDM Screening (Weeks 24 to 28)      │
│  2. Fetal Growth, Amniotic Fluid Index (AFI) & Doppler Scan (Wks 28-34)│
│  3. Group B Streptococcus / GBS Culture Swab (Weeks 36 to 37)          │
└────────────────────────────────────────────────────────────────────────┘

1. Screening for Gestational Diabetes Mellitus (Weeks 24 to 28)

Placental hormones—including Human Placental Lactogen (hPL), progesterone, cortisol, and prolactin—peak in late second trimester, inducing insulin resistance. Screening between 24 and 28 weeks identifies impaired glucose tolerance before it causes complications like fetal macrosomia ($> 4.0 \text{ kg}$) or shoulder dystocia.

Diagnostic Screening Protocols

1. International Association of Diabetes and Pregnancy Study Groups (IADPSG 1-Step 75g OGTT): Requires an 8- to 12-hour overnight fast. Blood is drawn fasting, then 1 hour and 2 hours after consuming a 75g oral glucose solution.
   • Fasting Threshold: $\ge 92 \text{ mg/dL } (5.1 \text{ mmol/L})$
   • 1-Hour Threshold: $\ge 180 \text{ mg/dL } (10.0 \text{ mmol/L})$
   • 2-Hour Threshold: $\ge 153 \text{ mg/dL } (8.5 \text{ mmol/L})$
   • Diagnosis: Meeting or exceeding any single value confirms Gestational Diabetes Mellitus (GDM).
2. Two-Step Approach (50g Glucose Challenge Test followed by 100g OGTT): A 50g non-fasting screen is performed first. If 1-hour blood glucose is $\ge 135\text{–}140 \text{ mg/dL}$, a fasting 3-hour 100g OGTT confirms or rules out GDM.

2. Third-Trimester Fetal Growth & Color Doppler Scan (Weeks 28 to 34)

Evaluates whether the fetus is growing along normal percentiles and verifies placental blood supply:

• Biometric Ultrasound Percentiles: Measures Biparietal Diameter (BPD), Head Circumference (HC), Abdominal Circumference (AC), and Femur Length (FL) to calculate Estimated Fetal Weight (EFW).
  • Intrauterine Growth Restriction (IUGR) / Small for Gestational Age (SGA): EFW falling below the 10th percentile requires vascular Doppler evaluation.
  • Large for Gestational Age (LGA): EFW exceeding the 90th percentile warrants evaluation for maternal hyperglycemia.
• Amniotic Fluid Volume Assessment:
  • Amniotic Fluid Index (AFI): Sums the deepest fluid pockets across four abdominal quadrants. Normal range is $8.0 \text{ to } 24.0 \text{ cm}$.
  • Oligohydramnios ($\text{AFI} < 5 \text{ cm}$): Low fluid levels require evaluation for placental insufficiency or membrane rupture.
  • Polyhydramnios ($\text{AFI} > 24 \text{ cm}$): Excess fluid levels require evaluation for maternal diabetes or fetal swallowing anomalies.
• Color Doppler Perfusion Indexing: Measures blood flow resistance across key vascular beds:
  1. Umbilical Artery (UA) Doppler: Evaluates placental vascular resistance.
  2. Middle Cerebral Artery (MCA) Doppler: Detects compensatory head-sparing responses or fetal anemia.
  3. Ductus Venosus (DV) Doppler: Evaluates right cardiac overload in severe fetal growth restriction.

3. Group B Streptococcus (GBS) Screening (Weeks 36 to 37)

Group B Streptococcus (Streptococcus agalactiae) is a bacterium naturally present in the lower genital and gastrointestinal tracts of roughly 20% to 30% of healthy pregnant individuals.

• Screening Procedure: A simple swab collects bacterial samples from the lower vagina and rectum between weeks 36 and 37.
• Clinical Action Plan: GBS colonization is typically harmless to the mother, but exposed newborns can develop severe early-onset GBS disease, including neonatal sepsis, pneumonia, or meningitis. Patients who test positive receive intrapartum intravenous penicillin or ampicillin prophylaxis during labor, protecting the baby during delivery.

Technical Comparison Matrix of Trimester Screening Tests

Screening Test	Trimester & Window	Primary Biomarkers / Parameters	Target Conditions Screened	Sensitivity / Accuracy
Baseline Blood Panel	First (Wks 4–10)	Hb, ABO/Rh, Rubella IgG, HIV, VDRL	Anemia, Rh isoimmunization, Infections	High diagnostic accuracy
NIPT (Cell-Free DNA)	First (Wk 10+)	Circulating placental cfDNA fragments	Trisomy 21, 18, 13, Sex Chromosomes	$> 99\%$ for Trisomy 21
Combined NT + Double Marker	First (Wks 11–13+6)	NT thickness, Free $\beta$-hCG, PAPP-A	Down, Edwards & Patau Syndromes	$\sim 85\text{–}90\%$ detection rate
Quadruple Marker	Second (Wks 15–20)	AFP, total hCG, uE3, Inhibin A	Neural Tube Defects, Trisomy 21 & 18	$\sim 80\text{–}85\%$ for Trisomy 21
TIFFA Anomaly Scan	Second (Wks 18–22)	Multi-organ 2D/3D structural biometry	Structural physical anomalies, Placenta previa	$\sim 75\text{–}85\%$ structural defects
75g OGTT (Glucose Test)	Third (Wks 24–28)	Fasting, 1-Hr, 2-Hr Plasma Glucose	Gestational Diabetes Mellitus (GDM)	Standard diagnostic threshold
Growth & Color Doppler	Third (Wks 28–34)	HC, AC, FL, AFI, Umbilical Artery Flow	IUGR, Placental failure, Oligohydramnios	High biometry accuracy
GBS Swab Culture	Third (Wks 36–37)	Vaginal/Rectal bacterial culture	Group B Streptococcal Neonatal Sepsis	High culture sensitivity

Step-by-Step Patient Pathway for Antenatal Screening

1.1. First Trimester Intake & Early Risk Profiling:Baseline Consultation.

Your doctor calculates your due date, reviews medical history, orders baseline maternal blood panels, and offers optional Non-Invasive Prenatal Testing (NIPT) starting at week 10.

2.2. Combined NT Ultrasound & Double Marker Test:Chromosomal Risk Window.

Between weeks 11 and 13+6, a specialized ultrasound measures nuchal translucency alongside a maternal blood draw for PAPP-A and Free $\beta$-hCG to evaluate trisomy risk.

3.3. Mid-Pregnancy TIFFA Anomaly Scan:Structural Evaluation.

Between weeks 18 and 22, a high-resolution ultrasound evaluates organ anatomy, brain structures, heart chambers, spine alignment, and placental location.

4.4. Glucose Tolerance & Growth Doppler Scans:Metabolic Check.

Between weeks 24 and 28, a 75g oral glucose tolerance test screens for gestational diabetes. Late third-trimester scans monitor growth percentiles and umbilical blood flow.

5.5. GBS Swab & Delivery Preparation:Pre-Labor Safety.

At weeks 36 to 37, a simple vaginal-rectal swab screens for Group B Strep to determine whether protective intrapartum antibiotics are needed during labor.

Cost Guidelines for Pregnancy Screening Tests in India

Screening costs vary depending on regional location, diagnostic laboratory accreditation (NABL/CAP), and fetal medicine specialization:

Antenatal Screening Test / Panel	Estimated Cost Range (INR)	Diagnostic Deliverables & Scope
Baseline Maternal Blood & Urine Panel	₹1,000 – ₹2,500	CBC, Blood Group/Rh, Blood Sugar, HIV, VDRL, HBsAg, Urine Culture.
First Trimester Double Marker Test	₹2,000 – ₹3,500	Biochemical screening for Free $\beta$-hCG and PAPP-A analytes.
Nuchal Translucency (NT) Ultrasound Scan	₹1,500 – ₹3,000	Fetal NT thickness, nasal bone assessment, early structural review.
Non-Invasive Prenatal Testing (NIPT)	₹12,000 – ₹25,000	Cell-free fetal DNA panel for Trisomy 21, 18, 13, and sex chromosomes.
Second Trimester Quadruple Marker Test	₹2,200 – ₹4,000	Biochemical serum screening for AFP, hCG, uE3, and Inhibin A.
TIFFA / Anomaly Ultrasound Scan	₹2,500 – ₹5,000	Comprehensive multi-organ structural evaluation and placental mapping.
75g Oral Glucose Tolerance Test (OGTT)	₹400 – ₹900	Fasting, 1-Hour, and 2-Hour venous blood glucose panel.
Growth & Color Doppler Ultrasound Scan	₹2,500 – ₹4,500	Fetal growth biometry, AFI measurement, and vascular blood flow.
Group B Strep (GBS) Culture Swab	₹600 – ₹1,200	Lower vaginal-rectal swab culture test.

Frequently Asked Questions (FAQs)

1. What is the primary difference between a screening test and a diagnostic test in pregnancy?

A screening test calculates the statistical probability or likelihood that a fetus may have a specific genetic or structural condition without posing any physical risk to the pregnancy. A diagnostic test (such as Amniocentesis or Chorionic Villus Sampling) analyzes fetal tissue directly to provide a definitive “yes” or “no” result, but carries a minor procedure-related risk.

2. Which screening tests are mandatory during the first trimester of pregnancy?

First-trimester essential screenings include baseline blood panels (Blood Group, Rh factor, CBC, Infectious Disease Panel), the First Trimester Combined Screening (NT Ultrasound + Double Marker blood test for PAPP-A and free beta-hCG), and optional Non-Invasive Prenatal Testing (NIPT).

3. What is Non-Invasive Prenatal Testing (NIPT) and how accurate is it?

NIPT analyzes cell-free fetal DNA circulating in maternal blood starting from 10 weeks of pregnancy. It offers greater than 99% detection rates for Down syndrome (Trisomy 21) and high accuracy for Trisomy 18 and Trisomy 13.

4. What is a Nuchal Translucency (NT) scan?

An NT scan is a specialized ultrasound performed between 11 weeks and 13 weeks + 6 days that measures the fluid collection behind the baby’s neck. Increased thickness (typically $\ge 3.0 \text{ mm}$) can indicate an elevated risk for chromosomal abnormalities or congenital heart defects.

5. When is the TIFFA or Anomaly scan performed during pregnancy?

The Targeted Imaging for Fetal Anomalies (TIFFA) or Anomaly scan is performed during the second trimester, between weeks 18 and 22, to evaluate fetal organ anatomy, brain structure, heart chambers, spine, limbs, and placental positioning.

6. What is the Quadruple Marker test and when is it recommended?

The Quad Marker is a second-trimester blood test performed between 15 and 20 weeks. It measures AFP, hCG, Unconjugated Estriol (uE3), and Inhibin A to screen for neural tube defects (like spina bifida) and chromosomal trisomies, especially if first-trimester screening was missed.

7. Why is screening for Gestational Diabetes Mellitus (GDM) performed between 24 and 28 weeks?

Placental hormones (hPL, progesterone, cortisol) peak during the second trimester, inducing physiological maternal insulin resistance. Screening between weeks 24 and 28 detects impaired glucose tolerance before it causes fetal macrosomia or delivery complications.

8. What is the Group B Streptococcus (GBS) swab test in the third trimester?

The GBS test involves a simple swab of the lower vagina and rectum performed between 36 and 37 weeks. If GBS bacteria are detected, intravenous antibiotics are administered during labor to protect the newborn from serious systemic infection.

9. Are routine ultrasound screening tests safe for the baby?

Yes, medical ultrasound uses high-frequency acoustic sound waves, not ionizing radiation. Decades of clinical studies show that diagnostic ultrasound following ALARA guidelines is completely safe for both mother and fetus.

10. What happens if a pregnancy screening test shows a high-risk result?

A high-risk screening result does not confirm a disorder. It indicates that further evaluation is recommended. Patients are typically referred to a fetal medicine specialist or genetic counselor to discuss confirmation options like high-resolution ultrasound, NIPT, CVS, or Amniocentesis.

11. How much do pregnancy screening tests cost on average in India?

Basic blood tests range from ₹500 to ₹1,500. Ultrasound scans (NT, TIFFA, Doppler) cost between ₹1,500 and ₹4,500 each. Advanced genetic blood tests like NIPT range from ₹12,000 to ₹25,000 depending on the panel selected.

12. Why is Rh typing important in early pregnancy screening?

If an Rh-negative mother carries an Rh-positive fetus, maternal red blood cells may produce antibodies against fetal blood cells (Rh isoimmunization). Identifying Rh status early allows timely administration of Anti-D immunoglobulin to prevent hemolytic disease of the newborn.

13. What is measured during a third-trimester Growth and Doppler scan?

A third-trimester growth scan measures fetal biometry (head circumference, abdominal circumference, femur length) to calculate estimated fetal weight, assesses amniotic fluid volume (AFI), and evaluates placental vascular resistance via Doppler ultrasound.

14. Can I skip screening tests if I have no family history of genetic disorders?

Over 80% of babies born with chromosomal variations or structural defects are born to parents with no prior family history or known risk factors. Universal screening is recommended for all pregnancies regardless of background.

15. What is the difference between Double Marker and Quadruple Marker tests?

The Double Marker is performed in the first trimester (weeks 11–13+6) measuring two analytes (free beta-hCG and PAPP-A). The Quadruple Marker is performed in the second trimester (weeks 15–20) measuring four analytes (AFP, hCG, uE3, Inhibin A) and adds screening for open neural tube defects.